Facing aggressive price cuts at home, Chinese biotechs must go global

19 January 2021
china_credit_depositphotos_large-1

By Wang Fangqing

Chinese biotechs must keep their eyes on markets outside China if they want to survive and thrive, said speakers at the China Biomed conference held online on January 12.

“Prices cuts is a trend as authorities want to focus on affordability, but this brings great pressure on novel drug development, which entails a costly process,” said Sheng Zelin, chief executive at Suzhou-based Zelgen.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology